Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties.
about
Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2Contributions of human enzymes in carcinogen metabolismCytochrome P450 enzymes in the generation of commercial products.Summary of information on human CYP enzymes: human P450 metabolism data.Expansion of substrate specificity of cytochrome P450 2A6 by random and site-directed mutagenesis.Identification of amino acid residues involved in 4-chloroindole 3-hydroxylation by cytochrome P450 2A6 using screening of random libraries.Heterologous expression of xenobiotic mammalian-metabolizing enzymes in mutagenicity tester bacteria: an update and practical considerations.Significant increase in phenacetin oxidation on L382V substitution in human cytochrome P450 1A2Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2.What makes P450s work? Searches for answers with known and new P450s.Update information on human P450s.N-hydroxyarylamines.Rate-limiting steps in cytochrome P450 catalysis.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies.Directed-evolution analysis of human cytochrome P450 2A6 for enhanced enzymatic catalysis.Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide.Cytochrome P450: what have we learned and what are the future issues?Exploring the potential of xenobiotic-metabolising enzymes as biocatalysts: evolving designer catalysts from polyfunctional cytochrome P450 enzymes.Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.Directed evolution of cytochrome P450 enzymes for biocatalysis: exploiting the catalytic versatility of enzymes with relaxed substrate specificity.Structural features of cytochrome P450 1A associated with the absence of EROD activity in liver of the loricariid catfish Pterygoplichthys sp.High-throughput functional screening of steroid substrates with wild-type and chimeric P450 enzymes.Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors.Arginine to lysine 108 substitution in recombinant CYP1A2 abolishes methoxyresorufin metabolism in lymphoblastoid cells.A modeling approach to evaluate the balance between bioactivation and detoxification of MeIQx in human hepatocytes.Analysis of Cytochrome P450 Conserved Sequence Motifs between Helices E and H: Prediction of Critical Motifs and Residues in Enzyme Functions.A rational approach to Re-engineer cytochrome P450 2B1 regioselectivity based on the crystal structure of cytochrome P450 2C5.Cooperativity in oxidation reactions catalyzed by cytochrome P450 1A2: highly cooperative pyrene hydroxylation and multiphasic kinetics of ligand binding.Exploring PTDH-P450BM3 Variants for the Synthesis of Drug Metabolites.Modelling the metabolic action of human and rat CYP1A2 and its relationship with the carcinogenicity of heterocyclic amines
P2860
Q24297785-76D344AF-482E-4F8C-B284-85AD3DE9C2DCQ30520640-DA33835F-6F0E-462B-8345-E06D2F78B830Q31096798-6D0952CB-B0A9-488A-8E73-08E28159F20EQ32103802-FBF96B53-6EEF-4750-9729-A608367EA09CQ33224912-2D6371BA-90C6-4345-A31F-01892799B047Q33382575-A8EF516D-82D4-4879-8B5A-74FA2AB26D9FQ33942241-1404B29E-F744-47BD-AF4A-434DB8762B09Q34015653-AD2D90DC-12E2-47FF-8829-C4CC84524CECQ34039772-93F92D3C-AD8F-4EC0-A616-4C89777AA95CQ34119137-E4044732-60D6-402A-A27A-3D33E5F70551Q34627922-DB9516F3-A8D1-4A48-9002-D4A7422E021BQ34819128-50AE7873-F410-49C1-941E-940CA0F7D181Q35009284-ABE19D8B-FA40-4B5E-8F7C-AEEB682AAE76Q35015993-B846F22B-E077-415C-88D6-69C8764C95BAQ35115436-7E4E4B92-D6D7-43DB-B22C-DFEFABD8A605Q35364450-67AD1431-E11A-4D39-A526-633B752ACBBBQ35651931-8D3252A4-39D9-424F-B710-32EA5A6D57EEQ35828009-5BD1C708-4BE7-4A50-9A3D-9EA4E51FB6EDQ36060026-1AEDAB0A-5E6D-4346-908A-697784F7F774Q37378059-9FF997D0-F21D-479F-8F72-13B42FB56233Q38385149-A7D0F0A1-D1F2-4B1B-97DD-730D2161B8E9Q38810210-632F69BA-D347-4E05-8C4F-D0622449F58CQ40223754-103EE9DD-3647-43F8-9869-252A33492676Q40529215-7AF11BA3-8CD7-4191-8960-57A56CFEAFAAQ40730352-28131F09-C9E3-40ED-B7EC-67F25CA58470Q41602177-89946D5D-86E9-489E-B00F-1F49839AEE45Q42172367-AF38EF9B-E74C-443A-A815-9A51F590902DQ44333296-5CA9AE62-E9C5-45D0-949C-1A0624171227Q46813905-C7D0A397-31AB-4CD0-9891-FD1839931E99Q49579327-87873397-18C8-4C3F-81C1-E8FA44A79C38Q57991325-3FC62BCC-63E4-4DA5-94DE-41A4823D8BB5
P2860
Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Selection and characterization ...... altered catalytic properties.
@ast
Selection and characterization ...... altered catalytic properties.
@en
type
label
Selection and characterization ...... altered catalytic properties.
@ast
Selection and characterization ...... altered catalytic properties.
@en
prefLabel
Selection and characterization ...... altered catalytic properties.
@ast
Selection and characterization ...... altered catalytic properties.
@en
P2093
P356
P1433
P1476
Selection and characterization ...... altered catalytic properties.
@en
P2093
Guengerich FP
Josephy PD
P304
P356
10.1021/BI990142+
P407
P577
1999-04-01T00:00:00Z